# US 2022/0054402 A1 · Compositions and methods for extracting, stabilizing, and manufacturing stable dosage forms of psilocin, psychedelic drugs, entheogens, and medicinal mushrooms as nano-dimensional drug delivery structures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0054402 A1
- Document ID: US20220054402A1
- Status: Published application
- Kind: A1
- Application number: 17/518,091
- Filed: 2021-11-03
- Published: 2022-02-24
- Earliest claimed: 2020-11-05
- Inventors: RICHARD C KAUFMAN
- Web page: https://patentgrep.com/patent/US20220054402A1

## CPC

- A61K 9/0043: {Nose}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 36/078: {Psilocybe}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 2236/33: involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K 2236/50: Methods involving additional extraction steps
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

This invention discloses nano-dimensional compositions of psychedelic drugs, entheogens, and medicinal mushrooms formed from lipids, polymers, stabilizers, mucoadhesives, permeation enhancers, and chemical stabilizers for delivering stable dosage forms by intraoral, gastrointestinal, transdermal, and intranasal, routes of administration. Disclosed are unified product extraction and manufacturing of stable nano-dimensional dosage forms of psychedelic drugs, entheogen, and medicinal mushrooms, and methods for improving their pharmacokinetics, pharmacodynamics, and efficacy. Also disclosed are methods for dephosphorylating the precursor psilocybin into active psilocin molecules, and fast-acting, nano-dimensional structures of psychedelic drugs taken by intranasal and intraoral routes of administration producing activity onset in less than 10 minutes.

## Claims

### Claim 1

A nano-dimensional drug delivery compositional structure comprising:
psychedelic drug or entheogen or medicinal mushroom; lipids;
polymers; and
at least one ingredient selected from the group consisting of mucoadhesive, permeation enhancers, chemical stabilizers, and surfactants.

### Claim 2 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure is administered via the sublingual mucosa and buccal mucosa.

### Claim 3 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure is administered via the rectal or vaginal mucosa.

### Claim 4 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure is administered across nasal mucosal barriers.

### Claim 5 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure is administered from the nasal cavity into the brain bypassing the blood-brain barrier.

### Claim 6 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure is administered across nasal dermal and epidermal barriers.

### Claim 7

A self-emulsifying drug delivery system comprising:
a nano-milled psychedelic drug or entheogen or medicinal mushroom extract; lipids; surfactants; and emulsifiers.

### Claim 8

A natural extraction process for psilocybin mushrooms comprising:
combining, separating, dephosphorylating, and stabilizing psilocin molecules in a method of production.

### Claim 9 (depends on 8)

The natural extraction process of claim 8, performed using sonication.

### Claim 10 (depends on 8)

The natural extraction process of claim 8, performed using organic acids.

### Claim 11 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the psychedelic drug or entheogen or medicinal mushroom is present in the form of an extract, wherein the extract is prepared by an extraction process for separating, and stabilizing the psychedelic drug, or entheogen, or medicinal mushroom.

### Claim 12 (depends on 11)

The nano-dimensional compositional structure of claim 11, wherein extraction process further comprises sonification.

### Claim 13 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure can deliver a stable, standardized, and precise amount of a psychedelic drug, or entheogen, or medicinal medicine for therapy.

### Claim 14 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure has a size distribution from 25 nm to 195 nm.

### Claim 15 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the nano-dimensional structure increases the bioavailability of psychedelic drug, or entheogen, or medicinal mushroom 2-fold to 10-fold compared to bioavailability without a nano-dimensional compositional structure.

### Claim 16 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure decreases than an amount of a psychedelic drug, or entheogen, or medicinal mushroom extract 2-fold to 8-fold needed to illicit the same therapeutic effect compared to the therapeutic effect without a nano-dimensional structure.

### Claim 17 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure decreases the onset time of effects from intranasal or intraoral delivered psilocin to less than 20 minutes after the time of administration.

### Claim 18 (depends on 1)

The nano-dimensional compositional structure of claim 1, wherein the structure decreases the onset time of effect from an intranasal or intraoral delivered psychedelic drug, or entheogen, or medicinal mushroom extract to less than 20 minutes after the time of administration.
